Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The company will engage in investor meetings at the event, which is scheduled to take place in New York on Thursday, November 21, 2024.
Pulmonx (Nasdaq: LUNG), leader nei trattamenti minimamente invasivi per gravi malattie polmonari, ha annunciato la sua partecipazione al Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. L'azienda parteciperà a incontri con gli investitori durante l'evento, che si svolgerà a New York giovedì 21 novembre 2024.
Pulmonx (Nasdaq: LUNG), líder en tratamientos mínimamente invasivos para enfermedades pulmonares severas, ha anunciado su participación en el Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. La empresa participará en reuniones con inversionistas durante el evento, que está programado para llevarse a cabo en Nueva York el jueves 21 de noviembre de 2024.
Pulmonx (Nasdaq: LUNG), 중증 폐 질환을 위한 최소 침습 치료의 선두주자인 이 회사는 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum에 참여한다고 발표했습니다. 이 회사는 2024년 11월 21일 목요일에 뉴욕에서 열리는 이벤트에서 투자자 회의에 참여할 예정입니다.
Pulmonx (Nasdaq: LUNG), un leader dans les traitements mini-invasifs pour les maladies pulmonaires sévères, a annoncé sa participation au Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. L'entreprise participera à des réunions d'investisseurs lors de l'événement, prévu à New York le jeudi 21 novembre 2024.
Pulmonx (Nasdaq: LUNG), ein führendes Unternehmen für minimal-invasive Behandlungen von schweren Lungenerkrankungen, hat seine Teilnahme am Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum angekündigt. Das Unternehmen wird während der Veranstaltung, die am Donnerstag, den 21. November 2024, in New York stattfindet, an Investorenmeetings teilnehmen.
- None.
- None.
REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
When is Pulmonx (LUNG) participating in the Canaccord Genuity Healthcare Forum?
What type of event is Pulmonx (LUNG) attending in November 2024?
Where will the Canaccord Genuity Forum featuring Pulmonx (LUNG) take place?
What is Pulmonx's (LUNG) main business focus according to the announcement?
